Robust neutralizing antibodies to SARS-CoV-2 infection persist for months
By A. Wajnberg, F. Amanat, A. Firpo, D. Altman, M. Bailey, M. Mansour, Meagan McMahon, Philip Meade, D. R. Mendu, K. Muellers and 8 more. Science, 2020
1,071 citations recorded by the source corpus.
SARS-CoV-2 antibodies persist As the number of daily COVID-19 cases continues to mount worldwide, the nature of the humoral immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains uncertain. Wajnberg et al. used a cohort of more than 30,000 infected individuals with mild to moderate COVID-19 symptoms to determine the robustness and longevity of the anti–SARS-CoV-2 antibody response. They found that neutralizing antibody titers against the SARS-CoV-2 spike protein persisted for at least 5 months after infection. Although continued monitoring of this cohort will be needed to confirm the longevity and potency of this response, these preliminary results suggest that the chance of reinfection may be lower than is currently feared. Science, this issue p. 1227 Antibodies generated after mild to moderate SARS-CoV-2 infection are neutralizing and relatively stable for at least 5 months. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic with millions infected and more than 1 million fatalities. Questions regarding the robustness, functionality, and longevity of the antibody response to the virus remain unanswered. Here, on the basis of a dataset of 30,082 individuals screened at Mount Sinai Health System in New York City, we report that the vast majority of infected individuals with mild-to-moderate COVID-19 experience robust immunoglobulin G antibody responses against the viral spike protein. We also show that titers are relatively stable for at least a period of about 5 months and that anti-spike binding titers significantly correlate with neutralization of authentic SARS-CoV-2. Our data suggest that more than 90% of seroconverters make detectable neutralizing antibody responses. These titers remain relatively stable for several months after infection.
Subfields: Infectious Diseases, Radiology, Nuclear Medicine and Imaging
View Paper: https://www.semanticscholar.org/paper/8f258a90e66e8ab4cc6de3669c4120e3b7ebc57e
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Infectious Diseases
In Radiology, Nuclear Medicine and Imaging
Citations in the corpus
- A human coronavirus evolves antigenically to escape antibody immunity (2020, background): “Our reason for focusing on these sera is that their anti-229E neutralizing titers are comparable to anti-SARS-CoV-2 sera neutralizing titers several months after recovery from COVID-19 (Crawford et al., 2020a; Wajnberg et al., 2020) or receipt of the Moderna mRNA-1273 vaccine (Widge et al.”
- Adaptive immunity to SARS-CoV-2 and COVID-19 (2021, positive): “Muchmore data on immunememory are expected in the coming months, but data so far indicate that T cell memory, B cell memory, and antibodies are all likely to persist for years in most individuals infected by SARS-CoV-2 (Dan et al., 2021; Gaebler et al., 2020; Wajnberg et al., 2020; Zuo et al., 2020a”
- Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection (2021, background): “1016/S0140-6736(20)30566-3; pmid: 32171076”
- SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies (2021, neutral): “Reduced neutralization by plasma from convalescent patients SARS-CoV-2 infection can induce the production of neutralizing antibodies, and these antibodies are believed to contribute to protection from reinfection (Rodda et al., 2020; Wajnberg et al., 2020).”